To systematically evaluate the clinical efficacy of Bailing Capsule combined with angiotensin receptor blocker(ARB) in the treatment of chronic glomerulonephritis.Methods:PubMed，the Cochrane Library，Embase，China National Knowledge Infrastructure(CNKI)，China Science Periodical Database(CSPD)，Chinese Citation Database(CCD) and China Biology Medicine disc(CBMdisc) were searched to collect the randomized controlled trials(RCTs) on Bailing Capsule combined with ARB was compared with ARB alone in the treatment of chronic glomerulonephritis.The retrieval time was from the inception of the databases to April 21，2020.The relevant articles were analyzed by RevMan 5.3.Results:A total of 15 RCTs were included，involving 1 348 patients，with 679 in observation group(Bailing Capsule combined with ARB) and 669 in control group(ARB alone).The Meta-analysis revealed that the total effective rate of the observation group was higher than that of the control group (OR=3.90，95%CI 2.74 to 5.57，Z=7.53，P<0.000 01).Additionally，there was a significant difference in renal function improvement between the two groups(P<0.000 01).No obvious adverse reactions were found in both groups.Conclusion:Bailing Capsule combined with ARB is more effective and safer than ARB alone in the treatment of chronic glomerulonephritis on the basis of routine treatment.